International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA)

Antineutrophil cytoplasmic antibody (ANCA) tests are used to diagnose and monitor inflammatory activity in the primary systemic small vessel vasculitides. ANCA is best demonstrated in these diseases by using a combination of indirect immunofluorescence (IIF) of normal peripheral blood neutrophils and enzyme-linked immunosorbent assays (ELISAs) that detect ANCA specific for proteinase 3 (PR3) or myeloperoxidase (MPO). For ANCA testing in "new" patients, IIF must be performed on all serum samples. Serum samples containing ANCA, any other cytoplasmic fluorescence, or an antinuclear antibody (ANA) that results in homogeneous or peripheral nuclear fluorescence then should be tested in ELISAs for PR3-ANCA and MPO-ANCA. Optimally, ELISAs for PR3-ANCA and MPO-ANCA should be performed on all serum samples. Inclusion of the most recent positive sample in the IIF or ELISA may help demonstrate a change in antibody level. Reports should use recommended terms. Any report of positive neutrophil fluorescence issued before the ELISA results are available should indicate that positive fluorescence alone is not specific for the diagnosis of Wegener granulomatosis or microscopic polyangiitis and that decisions about treatment should not be based solely on the ANCA results.

[1]  S. Targan,et al.  A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. , 1990, The Journal of allergy and clinical immunology.

[2]  A. Wiik,et al.  Methods to detect autoantibodies to neutrophilic granulocytes , 1996 .

[3]  S. Mcmillan,et al.  Antineutrophil cytoplasmic antibodies in rheumatoid arthritis. , 1992, British Journal of Rheumatology.

[4]  C. Pusey,et al.  ANCA and predicting relapse in systemic vasculitis. , 1995, QJM : monthly journal of the Association of Physicians.

[5]  M. Arnaout,et al.  Wegener's granulomatosis autoantigen is a novel neutrophil serine proteinase. , 1989, Blood.

[6]  D. Jayne,et al.  Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. , 1990, Kidney international.

[7]  J. Grünfeld,et al.  Antineutrophil cytoplasmic antibodies (ANCA) directed against cathepsin G in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis , 1992, Clinical and experimental immunology.

[8]  A. Segal,et al.  Alpha-enolase: a novel cytosolic autoantigen in ANCA positive vasculitis. , 1993, Kidney international.

[9]  C. Kallenberg,et al.  Association between active Wegener's granulomatosis and anticytoplasmic antibodies. , 1989, Archives of internal medicine.

[10]  A. Wilk.  Granulocyte‐Specific Antinuclear Antibodies , 1980 .

[11]  A. Wiik,et al.  Rapid screening assay for anti-GBM antibody and ANCAs; an important tool for the differential diagnosis of pulmonary renal syndromes. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  R. Deremee.  Antineutrophil cytoplasmic autoantibody-associated diseases: a pulmonologist's perspective. , 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  R. Goldschmeding,et al.  Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy , 1993, The Lancet.

[14]  J. Jennette,et al.  Antineutrophil cytoplasmic autoantibody-associated diseases: a pathologist's perspective. , 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  R. Falk,et al.  Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. , 1989, The American journal of pathology.

[16]  C. Winearls,et al.  PROSPECTIVE STUDY OF RADIOIMMUNOASSAY FOR ANTIBODIES AGAINST NEUTROPHIL CYTOPLASM IN DIAGNOSIS OF SYSTEMIC VASCULITIS , 1987, The Lancet.

[17]  C. Kallenberg,et al.  Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA). A report on the second phase of an international cooperative study on the standardization of ANCA assays. , 1996, Journal of immunological methods.

[18]  D. Jewell,et al.  Anti-neutrophil nuclear antibody in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis. , 1989, Clinical and experimental immunology.

[19]  C. Hagen.  Standardization of solid phase assays for ANCA determination , 1997 .

[20]  D. Stroncek,et al.  Neutrophil alloantibodies react with cytoplasmic antigens: a possible cause of false-positive indirect immunofluorescence assays for antibodies to neutrophil cytoplasmic antigens. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[21]  B. Baslund,et al.  Some patients with anti‐myeloperoxidase autoantibodies have a C‐ANCA pattern , 1994, Clinical and experimental immunology.

[22]  A. Wiik,et al.  Specificities of anti‐neutrophil autoantibodies in patients with rheumatoid arthritis (RA) , 1997, Clinical and experimental immunology.

[23]  R. Falk,et al.  Frequency of anti‐bactericidal/permeability‐increasing protein (BPI) and anti‐azurocidin in patients with renal disease , 1996, Clinical and experimental immunology.

[24]  G. Gerken,et al.  Actin is a target antigen of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune hepatitis type-1. , 1997, Journal of hepatology.

[25]  C. Lockwood,et al.  Antigen specificity in hydralazine associated ANCA positive systemic vasculitis. , 1995, QJM : monthly journal of the Association of Physicians.

[26]  R. Porter.  Nomenclature of Systemic Vasculitides: Proposal of an International Consensus Conference , 1995 .

[27]  E. Böttinger,et al.  The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated condition. , 1996, Archives of internal medicine.

[28]  W. Gross,et al.  Autoantibodies directed against lysozyme: a new target antigen for anti-neutrophil cytoplasmic antibodies (ANCA). , 1993, Advances in experimental medicine and biology.

[29]  J. Savige,et al.  A review of immunofluorescent patterns associated with antineutrophil cytoplasmic antibodies (ANCA) and their differentiation from other antibodies. , 1998, Journal of clinical pathology.

[30]  E. Csernok,et al.  Antineutrophil cytoplasmic autoantibody-associated diseases: a rheumatologist's perspective. , 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[31]  C. Kallenberg,et al.  Antineutrophil Cytoplasmic Autoantibodies with Specificity for Myeloperoxidase , 1996 .

[32]  A. Wiik.  Antinuclear factors in sera from healthy blood donors. , 2009, Acta pathologica et microbiologica Scandinavica. Section C, Immunology.

[33]  J. Savige.  Detection of autoantibodies to neutrophil cytoplasmic antigens. , 1995, Journal of clinical pathology.

[34]  T. H. The,et al.  AUTOANTIBODIES AGAINST NEUTROPHILS AND MONOCYTES: TOOL FOR DIAGNOSIS AND MARKER OF DISEASE ACTIVITY IN WEGENER'S GRANULOMATOSIS , 1985, The Lancet.

[35]  M. Yoshida,et al.  Novel autoantigens of perinuclear anti‐neutrophil cytoplasmic antibodies (P‐ANCA) in ulcerative colitis: non‐histone chromosomal proteins, HMG1 and HMG2 , 1997, Clinical and experimental immunology.

[36]  D A Bloch,et al.  The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. , 2010, Arthritis and rheumatism.

[37]  A. Wiik.  Delineation of a standard procedure for indirect immunofluorescence detection of ANCA. , 1989, APMIS. Supplementum.

[38]  C. Hack,et al.  Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils. , 1989, The Journal of clinical investigation.